Assessing Clinical Trial Experiences of Patients With Osteosarcoma

Osteosarcoma Clinical Trial

Official title:

An Observational Study Investigating The Experiences of Patients In Osteosarcoma Clinical Trials

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05535283
• Other study ID #: 83926159
• Status: Not yet recruiting
• Start date: October 2024
• Est. completion date: October 2026

Study information

• Verified date: December 2023
• Source: Power Life Sciences Inc.
• Contact: Michael B Gill
• Phone: 4159004227
• Email: bask[@]withpower.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Clinical study participation has historically been heavily biased toward specific demographics. Several people will be invited to enroll in this study so that it may collect a variety of data about osteosarcoma clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. People with osteosarcoma who are invited to take part in medical research will benefit from the analysis of the data.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: October 2026
• Est. primary completion date: October 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient has been diagnosed with osteosarcoma
• Patient has self-identified as planning to enroll in an interventional clinical trial
• Patient is a minimum of 18 years or older

Exclusion Criteria:

• ECOG score of 4
• Patient is pregnant
• Inability to perform regular electronic reporting
• Patient does not understand, sign, and return consent form

Related Conditions & MeSH terms

• Osteosarcoma

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Power Life Sciences Inc.

References & Publications (3)

Bielack S, Carrle D, Jost L; ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008 May;19 Suppl 2:ii94-6. doi: 10.1093/annonc/mdn102. No abstract available. — View Citation

Burns L, Perisoglou M. Clinical trials in osteosarcoma treatment: patients' perspective through art. Recent Results Cancer Res. 2009;179:345-61. doi: 10.1007/978-3-540-77960-5_22. — View Citation

Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, Malawer MM. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002 Mar 15;65(6):1123-32. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients who decide to enroll in an osteosarcoma clinical trial		3 months
Primary	Rate of patients who remain in osteosarcoma clinical trial to trial completion		12 months